Skip to main content Skip to navigation
We care about your privacy. Read about your rights and how we protect your data. Get Details

Jeffrey Dome, MD, PhD

Vice President, Center for Cancer and Blood Disorders
Awards and Recognition:
    Top Doctors
    No. Va. Magazine
    (2015, 2016, 2017, 2018)
View My Research Profile


Languages Spoken

  • English


Board Certifications

  • American Board of Pediatrics/Hematology-Oncology

National Provider ID: 1902809197

This faculty member (or a member of their immediate family) has a working relationship (i.e. consulting, research, and/or educational services) with the companies listed below. These relations have been reported to the health system leadership and, when appropriate, management plans are in place to address potential conflicts.

Outside Interests

  • American Board of Pediatrics 
  • St Jude Children's Research Hospital 
  • Sigma-Tau Pharmaceuticals,, Inc. 



Jeffrey Dome, MD, PhD, is Vice President of the Center for Cancer and Blood Disorders, Chief of the Divisions of Hematology and Oncology, and Associate Director of the Center for Cancer and Immunology Research at Children’s National Health System in Washington, DC. He also is Professor of Pediatrics at the George Washington University School of Medicine & Health Sciences and the Thomas Willson and Lenore Williams McKnew Professor of Pediatric Oncology. Dr. Dome received his MD degree from the University of Pennsylvania School of Medicine and his PhD degree in Medicine from Erasmus University in Rotterdam. He completed a residency in Pediatrics at Yale-New Haven Hospital and a fellowship in Pediatric Hematology/Oncology at Johns Hopkins Hospital.

After fellowship, Dr. Dome was a faculty member at St. Jude Children’s Research Hospital before joining Children’s National Health System in 2006. Dr. Dome is an internationally recognized expert on pediatric solid tumors, with an emphasis on kidney tumors and sarcomas. He chaired the Children’s Oncology Group (COG) Renal Tumor Committee, which oversees clinical research on kidney tumors at more than 200 children’s hospitals around the world, for more than ten years. He is a member of the Hematology/Oncology Subboard of the American Board of Pediatrics and serves on numerous medical advisory boards for cancer foundations. Dr. Dome is the Chair of the organizing committee for the 2017 International Society of Pediatric Oncology (SIOP) meeting, to be held in Washington, DC. He has authored more than 150 articles, books and chapters on pediatric cancer.

Education & Training

Education & Training

  • Fellowship Program, Pediatric Hematology/Oncology, 1997
    Johns Hopkins Hospital
  • Residency Program, Pediatrics, 1994
    Yale-New Haven Hospital
  • Internship Program, Pediatrics, 1992
    Yale-New Haven Hospital
  • MD, 1991
    University of Pennsylvania School of Medicine
  • BA, 1987
    University of Pennsylvania
Patient Stories

Patient Stories: Jeffrey Dome

Amira rides a horse

Amira's Story

Despite the past decade spent in and out of the hospital, Amira has her sights set on a bright future and doesn’t allow her diagnosis to define who she is.



New Treatment Approach Significantly Improves Outcomes for Pediatric Patients with Kidney Cancer

A new approach to treating children diagnosed with bilateral Wilms tumors (BWT) significantly improved event-free survival (EFS), or the length of time a patient does not experience complications or recurrence of cancer following treatment, and overall survival (OS) rates after four years when compared to historical rates, according to a Children’s Oncology Group study published in the September issue of the Annals of Surgery.

Research & Publications

Research & Publications

Age at diagnosis as a prognostic factor for rhabdoid tumor of the kidney A report from the National Wilms Tumor Study Group

(2005) Journal of Clinical Oncology

Disappearance of the Telomere dysfunctioninduced stress response in fully senescent cells

(2004) Cancer Research

High telomerase RNA expression is an adverse prognostic factor for favorable histology Wilms tumor

(2005) Journal of Clinical Oncology

Improved survival for patients with recurrent Wilms tumor

(2002) Journal of Pediatric Hematology Oncology

Recent advances in Wilms tumor genetics

(2002) Current Opinion in Pediatrics

Telomerase expression predicts unfavorable outcome in osteosarcoma

(2004) Journal of Clinical Oncology

Telomere biology of pediatric cancer

(2007) Cancer Investigation

The feasibility and outcome of nephronsparing surgery for children with bilateral Wilms tumor The St Jude Childrens Research Hospital Experience 19992006

(2008) Cancer

Topotecan is active against Wilms tumor Results of a multiinstitutional phase II study

(2007) Journal of Clinical Oncology

Treatment of Anaplastic Histology Wilms Tumor Results from the Fifth National Wilms Tumor Study

(2006) Journal of Clinical Oncology

View publications on PubMed

Invest in future cures for some of life's most devastating diseases

See other ways to give
Share your birthday with a child. Celebrate your life, and give a chance to someone who desperately wants to have as many as you. Share your birthday with a child. Celebrate your life, and give a chance to someone who desperately wants to have as many as you. Make it happen

Craig Woodside's Story

Craig Woodside with patient

Craig Woodside always wanted to be in the medical profession, but it took him a bit of trial and error to find the right patients.

Read More of Craig Woodside's Story